NeuroSense Therapeutics
Creatively and diligently moving fast towards an effective treatment for people with ALS.
Creatively and diligently moving fast towards an effective treatment for people with ALS.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a pioneering **Biotech** startup, founded in **2017**, with a clear focus on advancing research and development in the treatment of Amyotrophic Lateral Sclerosis (ALS) and other Central Nervous System (CNS) indications. The company's **slogan**, "Creatively and diligently moving fast towards an effective treatment for people with ALS," reflects their commitment and drive in this critical healthcare segment. Currently, the company is conducting a Phase 2b, double-blind, randomized, placebo-controlled clinical study in **ALS** patients globally, signaling a significant milestone in their pursuit of breakthrough therapies for neurodegenerative diseases. NeuroSense Therapeutics recently secured a noteworthy **$4.50M** Post-IPO Equity investment on **10 April 2024**, indicating **Investor** confidence in the company's potential. With headquarters in the **United States**, NeuroSense Therapeutics is poised to make substantial contributions to the biotechnology landscape and transform the treatment landscape for ALS and related CNS conditions. Their persistent focus on addressing critical unmet medical needs makes them a compelling prospect for investors seeking to support innovative solutions in the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $4.50M | - | 10 Apr 2024 | |
| Post-IPO Equity | $4.50M | - | 22 Jun 2023 | |
| Equity Crowdfunding | $529.00K | 1 |
|
01 Feb 2020 |
No recent news or press coverage available for NeuroSense Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
